ByteDance's AI Drug-Discovery Spin-Off Anew Labs Raises $290M at a $1.5 Billion Valuation

ByteDance, the Chinese internet giant that owns TikTok, has completed a $290 million external fundraising for Anew Labs, its AI-driven drug-discovery unit, following the unit's formal spin-off from the parent company. Two people with direct knowledge of the transaction confirmed the deal to Reuters. Shanghai-headquartered Anew Labs achieved a post-money valuation of approximately $1.5 billion in its first-ever external financing round. ByteDance will retain roughly 56% of the business after the round, meaning the spin-off remains firmly under its strategic control despite bringing in outside capital.

The round was led by HSG (formerly known as Sequoia China), IDG Capital, and GL Ventures, the venture arm of Hillhouse Investment, with 5Y Capital acting as co-lead. Additional participants included Gaorong Ventures, Primavera Venture Partners, and Boyu Capital, alongside strategic investor SBP Group and the state-backed Shanghai Future Industries Fund.

Anew Labs operates a set of AI platforms for biomolecular structure prediction and design, antibody design and optimization, and drug discovery, branded internally as AnewFold, AnewDesign, and AnewMind. Its pipeline includes a small-molecule drug candidate, a drug targeting a cell-surface protein, and two undisclosed targets, most notably an IL-17 inhibitor relevant to autoimmune diseases such as psoriasis and ankylosing spondylitis, a program reported to be in lead optimization. The company is led by Liu Kai, a former IDG Capital venture capitalist, and operates out of Shanghai, with additional offices in Singapore and San Francisco. Volcano Engine, ByteDance's cloud computing arm, continues to supply its computing infrastructure, a detail that quietly preserves a structural dependency on the parent company even after the corporate spin-off.

The rationale behind the spin-off is telling: ByteDance executives reportedly concluded that AI-for-science work follows a fundamentally different operating logic and timeline than the group's core consumer-internet business. Drug discovery moves on laboratory and clinical timescales that do not align with the quarterly release cadence of a social-media company, and separating the unit allows it to attract healthcare-focused investors who might otherwise be wary of exposure to ByteDance's broader regulatory and consumer-platform volatility, most notably the ongoing TikTok divestiture saga in the United States.

Anew Labs is not an isolated case but the latest instance of a pattern that has become increasingly visible across China's largest consumer-internet companies over the past eighteen months. Alibaba has steadily built out its own biomedical AI research division within its DAMO Academy, Tencent has backed multiple AI-drug-discovery ventures through its investment arm, and Baidu has explored protein-structure and molecular-design applications tied to its own foundation-model stack. What distinguishes the Anew Labs transaction is the scale of conviction shown by outside capital on a first external round, and the explicit decision to fully carve the unit out as an independently governed entity rather than keeping it as an internal research lab reporting through the parent's ordinary product organization. This matters for two reasons. First, it creates a cleaner asset for eventual monetization, whether through a future IPO, a strategic sale to a pharmaceutical partner, or licensing deals, that would be far messier to execute from inside a diversified conglomerate whose valuation is dominated by short-video advertising economics. Second, it allows ByteDance to ring-fence a portion of its AI research talent and compute allocation into a vehicle explicitly optimized for long-horizon, capital-intensive science, which may prove more resilient to the kind of internal reprioritization that can occur when a parent company faces its own margin pressure or regulatory distraction, as ByteDance currently does on multiple fronts simultaneously.

It is also worth situating this deal within the broader financing environment for AI-native biotech in China this month, a period that has also seen Nutshell Therapeutics close a Series C1 round and Apex Intelligence pursue its own angel-stage AI-science fundraising, suggesting that AI-for-science, and computational drug discovery specifically, is emerging as a distinct and increasingly well-capitalized sub-vertical within China's broader AI investment landscape, somewhat insulated from the direct regulatory pressure weighing on generative foundation-model labs, yet still dependent on many of the same underlying compute and talent resources.

Committing $290 million to a company's very first external financing round, for a business that has not yet advanced a single candidate into clinical trials, is an unusually aggressive bet even by the standards of 2026's AI funding environment. The $1.5 billion valuation instantly places Anew Labs among the highest-valued AI drug-discovery companies in China and sets a new benchmark for how the market is pricing pre-clinical, AI-native biotech platforms, well ahead of the stage at which most biotech startups historically reach unicorn status. The composition of the syndicate, HSG, IDG Capital, and Hillhouse are not spray-and-pray investors, signals a considered institutional conviction rather than a speculative momentum bet, reinforced by the presence of the state-backed Shanghai Future Industries Fund, which lends the round an implicit dimension of local industrial-policy endorsement.

This case sits at the intersection of two structural trends: the migration of Chinese mega-cap platform companies into AI-for-science verticals, echoing Alibaba's and Tencent's own biotech-AI investments, and the broader rotation of Chinese venture capital toward AI applications with tangible scientific or physical output rather than further foundation-model wrappers. For a foreign investor, the key vulnerability is structural rather than regulatory: ByteDance's 56% retained stake means Anew Labs' governance, strategic direction, and, critically, its compute supply chain remain tethered to a parent company that is itself subject to intense, unresolved US regulatory scrutiny over TikTok. Any escalation in the ByteDance-US relationship could, in principle, spill over into Anew Labs' operations given its continued reliance on Volcano Engine infrastructure, even though the entity itself sits outside the direct line of fire faced by AI labs named in recent national-security advisories. We recommend treating Anew Labs less as a standalone diversification play and more as a derivative exposure to ByteDance's own geopolitical risk profile.

A further layer of diligence worth flagging concerns minority-shareholder protections in a structure where the parent retains majority control. Outside investors committing $290 million into a 44%-aggregate minority position are, in effect, trusting ByteDance's continued strategic commitment to a business line entirely outside its core competency and revenue base. Should ByteDance face acute financial or regulatory pressure on its core advertising and short-video business, a scenario that cannot be excluded given the unresolved TikTok situation, Anew Labs could become a candidate for either accelerated divestment, potentially favorable to minority holders seeking liquidity, or deprioritized internal support, unfavorable given the unit's continued reliance on parent-supplied compute. We recommend that any prospective co-investor in a future Anew Labs round seek explicit contractual protections regarding continuity of Volcano Engine compute access and governance rights disproportionate to the minority equity stake, given the atypical parent-subsidiary dynamics at play here relative to a fully independent biotech startup.

We will track four items: first, whether Anew Labs' IL-17 inhibitor or any other candidate advances into IND-enabling studies or formal clinical trials, which would be the first real test of the platform's scientific output beyond model demonstrations; second, whether ByteDance reduces its 56% stake over time as the unit matures, a move that would signal a genuine arm's-length separation rather than a capital-raising exercise for an effectively captive subsidiary; third, whether other Chinese consumer-internet giants replicate this spin-off structure for their own AI-for-science divisions in the coming quarters; and fourth, any indication of how the unresolved TikTok-US situation might affect ByteDance's broader capital-allocation priorities, and by extension its willingness to continue supporting Anew Labs' compute needs through Volcano Engine over a multi-year horizon.